Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + calcineurin inhibitor + methotrexate
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination prophylactic regimen is being investigated by Zhejiang University for the prevention of graft-versus-host disease (GVHD) in patients undergoing HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). The regimen consists of ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, administered in combination with a calcineurin inhibitor (such as tacrolimus or cyclosporine) and a short course of methotrexate. Ruxolitinib works by blocking the signaling of proinflammatory cytokines involved in the pathogenesis of GVHD. This triple-drug combination is being evaluated as an alternative to the standard mycophenolate mofetil (MMF)-based prophylaxis in the context of low-dose antithymocyte globulin (ATG) systems to reduce the incidence of acute and chronic GVHD.
- Other names
- ruxolitinib + CNI + MTX
02
Targets
Beyond the preview
Go deeper on ruxolitinib + calcineurin inhibitor + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + calcineurin inhibitor + methotrexate.